Y-mAbs Therapeutics (NASDAQ:YMAB) Earns “Outperform” Rating from Wedbush

Wedbush reiterated their outperform rating on shares of Y-mAbs Therapeutics (NASDAQ:YMAB) in a research note published on Friday morning,RTT News reports. Wedbush currently has a $23.00 price objective on the stock.

A number of other equities analysts have also commented on the stock. Oppenheimer assumed coverage on shares of Y-mAbs Therapeutics in a research note on Monday, November 18th. They issued an “outperform” rating and a $23.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating on shares of Y-mAbs Therapeutics in a research note on Wednesday, December 11th. Finally, Brookline Capital Management assumed coverage on shares of Y-mAbs Therapeutics in a research note on Thursday, December 5th. They issued a “buy” rating and a $17.00 price objective for the company. One research analyst has rated the stock with a sell rating, seven have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $20.89.

Y-mAbs Therapeutics Price Performance

NASDAQ YMAB opened at $6.89 on Friday. Y-mAbs Therapeutics has a 12 month low of $6.84 and a 12 month high of $20.90. The firm has a market capitalization of $308.60 million, a PE ratio of -12.76 and a beta of 0.69. The company’s 50 day simple moving average is $10.47 and its 200 day simple moving average is $12.16.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its quarterly earnings data on Friday, November 8th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). The company had revenue of $18.46 million for the quarter, compared to analyst estimates of $23.38 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. During the same quarter in the prior year, the business earned ($0.18) EPS. Sell-side analysts anticipate that Y-mAbs Therapeutics will post -0.66 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of YMAB. Caligan Partners LP raised its holdings in Y-mAbs Therapeutics by 105.3% in the 3rd quarter. Caligan Partners LP now owns 1,195,253 shares of the company’s stock worth $15,718,000 after acquiring an additional 613,175 shares during the period. State Street Corp raised its holdings in Y-mAbs Therapeutics by 50.4% in the 3rd quarter. State Street Corp now owns 1,209,781 shares of the company’s stock worth $15,909,000 after acquiring an additional 405,169 shares during the period. Squarepoint Ops LLC raised its holdings in Y-mAbs Therapeutics by 143.4% in the 2nd quarter. Squarepoint Ops LLC now owns 126,389 shares of the company’s stock worth $1,527,000 after acquiring an additional 74,452 shares during the period. Millennium Management LLC raised its holdings in Y-mAbs Therapeutics by 23.8% in the 2nd quarter. Millennium Management LLC now owns 349,784 shares of the company’s stock worth $4,225,000 after acquiring an additional 67,233 shares during the period. Finally, Dimensional Fund Advisors LP raised its holdings in Y-mAbs Therapeutics by 15.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company’s stock worth $5,853,000 after acquiring an additional 65,732 shares during the period. Institutional investors own 70.85% of the company’s stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.